Wells Fargo lowered the firm’s price target on Inspire Medical (INSP) to $145 from $160 and keeps an Overweight rating on the shares. The firm notes the company sounded confident that it can work through reimbursement confusion, but Wells sees possible near-term disruption. The firm expects update on Q4 call but full clarity may take longer.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems Issues Strong Preliminary 2025 Revenue Results
- Inspire Medical names Matt Osberg as new CFO
- Inspire Medical sees Q4 revenue $268.9M-$269.1M, consensus $262.3M
- Inspire Medical sees FY26 revenue $1.003B-$1.013B, consensus $1B
- Inspire Medical weakness related to another MAC pulling CPT code